Target intelligence / Profile preview

Pathogens, toxins, and autoantigens bound by Fab regions

Molecular classification
Other
01

Overview

Pathogens, toxins, and autoantigens bound by Fab regions represent a broad functional category of molecular entities recognized by the adaptive immune system and targeted by antibody-based therapies. The Fragment antigen-binding (Fab) region is the portion of an antibody molecule that confers specificity, containing the variable domains that form the binding site for a specific epitope on an antigen (Janeway et al., Immunobiology, 2001). In clinical pharmacology, this category includes a diverse array of targets such as viral proteins, bacterial toxins, pro-inflammatory cytokines like TNF-alpha, and small molecule drugs like digoxin or dabigatran (Nelson, Nature Reviews Drug Discovery, 2010; Pollack et al., NEJM, 2015). Drugs designed to interact with these targets, such as monoclonal antibodies or engineered Fab fragments, work by neutralizing the target's toxicity or blocking its ability to bind to physiological receptors. Because this term aggregates thousands of unrelated molecular species across infectious, oncological, and autoimmune disciplines, it is classified as a functional description of antigen-antibody interaction rather than a single discrete therapeutic target.

Other names
AntigensEpitopesFab-binding targetsImmunogensAntibody targets
02

Mechanism of action

Therapeutic Fab fragments or full-length antibodies bind to these targets via the variable regions (paratopes) to induce steric hindrance, neutralize biological activity, prevent receptor-ligand interactions, or facilitate clearance from circulation (Janeway et al., Immunobiology, 2001; Nelson, Nature Reviews Drug Discovery, 2010).

03

Biological functions

Immune responseAntigen recognitionNeutralizationOpsonization
04

Disease associations

InfectionAutoimmune diseaseIntoxicationCancerInflammation
05

Safety considerations

Immunogenicity and anti-drug antibody formationHypersensitivity reactionsOff-target bindingRapid renal clearance of isolated Fab fragmentsLack of Fc-mediated effector functions in Fab-only therapeutics
06

Interacting drugs

Ranibizumab

7 more in the full profile.

07

Biomarkers

Free antigen concentrationAntibody-antigen complex levelsAnti-drug antibodies (ADA)Serum drug levels

Beyond the preview

Go deeper on Pathogens, toxins, and autoantigens bound by Fab regions.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogens, toxins, and autoantigens bound by Fab regions.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call